| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
25002 |
| Drug |
Sodium thiosulfate |
| Brand |
Pedmarqsi® |
| Indication |
Sodium thiosulfate (Pedmarqsi®) is indicated for the prevention of ototoxicity caused by cisplatin chemotherapy in patients one month to < 18 years of age with localised, non-metastatic, solid tumours. |
| Rapid review commissioned |
08/01/2025 |
| Rapid review completed |
06/02/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of sodium thiosulfate (Pedmarqsi®) compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
26/03/2025 |
| Pre-submission consultation with Applicant |
16/04/2025 |
